期刊文献+

乳腺癌分子分型与腋窝淋巴结外科处理 被引量:1

Molecular Classification of Breast Cancer and Surgical Management of Axiuary Lymph Node
原文传递
导出
摘要 目的探讨乳腺癌分子分型是否影响腋窝淋巴结的术式选择。方法检索有关乳腺癌分子分型与腋窝淋巴结转移情况的文献并进行综述。结果三阴型乳腺癌患者的前哨淋巴结与非前哨淋巴结阳性率均较低,luminalB型和HER-2过表达型患者的腋窝淋巴结转移率较高,尤其是luminalB型乳腺癌患者,其前哨淋巴结阳性率、非前哨淋巴结阳性率均较其他分子分型高,对于行保乳手术的老年患者,当仅有1~2枚前哨淋巴结转移时,可免行腋窝淋巴结清扫;对于肿瘤体积较大的年轻患者,即使前哨淋巴结阴性,非前哨淋巴结阳性的可能性仍然较大,行腋窝淋巴结清扫可能会使这部分患者受益。结论对于腋窝淋巴结的术式选择,乳腺癌分子分型也是需要考虑的因素之一。 Objective To explore influence of molecular classification of breast cancer on surgical treatment of axillary lymph nodes. Method The related literatures which discussed the relation between molecular classi- fication and axillary lymph node metastasis were reviewed and analyzed. Results The triple negative breast cancer had a lower rate of sentinel lymph node or non-sentinel lymph node metastasis. The axillary lymph node metastasis rate was higher in the luminal B or HER-2 overexpression subtypes. Especially, luminal B subtype' had a higher risk of sentinel lymph node or non-sentinel lymph node metastasis as compared with the other subtypes, Elderly patients with breast conserving operation could be free for axillary lymph node dissection when only 1-2 sentinel lymph node metastases. There was still a positive possibility of non-sentinel lymph node for younger patients with a larger tumor size, even if the sentinel lymph node negative, the lymph node dissection may benefit these patients. Conclusion Breast cancer molecular classification should be considered for the surgery selection of axillary lymph node dissection.
出处 《中国普外基础与临床杂志》 CAS 2014年第5期589-592,共4页 Chinese Journal of Bases and Clinics In General Surgery
关键词 乳腺癌 分子分型 前哨淋巴结 非前哨淋巴结 腋窝淋巴结清扫术 Breast cancer Molecular classification Sentinel lymph node Non-sentinel lymph node Axillary lymph node dissection
  • 相关文献

参考文献19

  • 1Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypesdealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747. 被引量:1
  • 2Wiechmann L,Sampson M,Stempel M,et al.Presenting features of breast cancer differ by molecular subtype[J].Ann Surg Oncol,2009,16(10):2705-2710. 被引量:1
  • 3Gabos Z,Thoms J,Ghosh S,et al.The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer[J].Breast Cancer Res Treat,2010,124(1):187-194. 被引量:1
  • 4Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502. 被引量:1
  • 5NCCN Clinical Practice Guidelines in Oncology:Breast Cancer[EB/OL].Ver 1.2010.http://www.nccn.com/. 被引量:1
  • 6Zakaria S,Pantvaidya G,Reynolds CA,et al.Sentinel node positive breast cancer patients who do not undergo axillary dissection:are they different ?[J].Surgery,2008,143(5):641-647. 被引量:1
  • 7Hwang RF,Gonzalez-Angulo AM,Yi M,et al.Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection[J].Cancer,2007,110(4):723-730. 被引量:1
  • 8Takei H,Suemasu K,Kurosumi M,et al.Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer[J].Breast Cancer,2007,14(1):16-24. 被引量:1
  • 9Giuliano AE,Hunt KK,Ballman KV,et al.Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial[J].JAMA,2011,305(6):569-575. 被引量:1
  • 10NCCN Clinical Practice Guidelines in Oncology:Breast Cancer[EB/OL].Ver 1.2012.http: //www.nccn.com/. 被引量:1

同被引文献24

  • 1吴国球,张臣,孙宏伟,赵成桂,芦惠霞.建立人乳腺珠蛋白mRNA FQ-PCR方法用于乳腺癌微小转移的诊断[J].临床检验杂志,2006,24(2):85-88. 被引量:3
  • 2Illyes I,Tokes AM,Kovacs A,et al.In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.Virchows Arch,2014,465(1): 15-24. 被引量:1
  • 3Gujam FJ,Going JJ,Mohammed ZM,et al.Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer.BMC Cancer,2014,14: 676. 被引量:1
  • 4Tjensvoll K,Oltedal S,Farmen RK,et al.Disseminated tumor cells in bone marrow assessed by TWIST1,cytokeratin 19,and mammaglobin A mRNA predict outcome in operable breast cancer patients.Clin Breast Cancer,2010,10(5): 378-384. 被引量:1
  • 5Dono M,Ferro P,Benedetti L,et al.Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis.J Neurooncol,2009,91(3): 295-298. 被引量:1
  • 6Osako T,Iwase T,Ushijima M,et al.Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.Cancer Sci,2014,105(5):576-582. 被引量:1
  • 7Osako T,Iwase T,Kimura K,et al.Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis.Cancer Sci,2013,104(4): 453-457. 被引量:1
  • 8Lee GW,Kim JY,Koh EH,et al.Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer.Genet Mol Res,2012,11(4): 4034-4042. 被引量:1
  • 9Zhao S,Yang H,Zhang M,et al.Circulating tumor cells (CTCs) detected by triple-marker EpCAM,CK19,and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.Cell Biochem Biophys,2013,65(2): 263-273. 被引量:1
  • 10Strati A,Markou A,Parisi C,et al.Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.BMC Cancer,2011,11: 422. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部